All In Biotech

Drug Trial Radar · NCT06859853

A Study to Evaluate MWN109 Injection in Healthy Subjects

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWN109 Injection in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Apr 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Mar 17, 2025

Primary completion

Sep 25, 2025

Study completion Nov 25, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a Phase1, randomized, double-blinded, and placebo-controlled study. In each cohort, enrolled participants will be randomized to receive either placebo or MWN109.

Conditions

  • Overweight or Obese

Interventions

  • PlaceboDrug

    Sub cutaneous injection on the abdomen by a qualified member of study staff.

  • Subcutaneous single and mutiple doseDrug

    Sub cutaneous injection on the abdomen by a qualified member of study staff.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Incidence of treatment emergent adverse events (TEAEs) following treatment administrationTime frame: Part A- Up to Day 29; Part B- Up to Day 50 post first dose administration
  2. Number of participants with change in laboratory parameters following treatment administrationTime frame: Part A- Up to Day 29; Part B- Up to Day 50 post first dose administration
  3. Number of participants with change in Vital signs following treatment administrationTime frame: Part A- Up to Day 29; Part B- Up to Day 50 post first dose administration
  4. Incidence of anti-drug antibody (ADA) formation following treatment administrationTime frame: Part A- Up to Day 29; Part B- Up to Day 50 post first dose administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Veritus Research

    Melbourne, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.